Quest PharmaTech Inc. (CVE:QPT – Get Free Report) shares reached a new 52-week low on Monday . The stock traded as low as C$0.02 and last traded at C$0.03, with a volume of 192998 shares traded. The stock had previously closed at C$0.03.
Quest PharmaTech Stock Performance
The company has a fifty day moving average of C$0.03 and a 200-day moving average of C$0.03. The company has a current ratio of 0.40, a quick ratio of 0.52 and a debt-to-equity ratio of 4.35. The company has a market capitalization of C$4.23 million, a price-to-earnings ratio of 0.83 and a beta of 0.00.
About Quest PharmaTech
Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.
See Also
- Five stocks we like better than Quest PharmaTech
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
